Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

177.20 +0.74 (+0.42%)
Official Closing Price Updated: 6:30 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for patients, avoiding surgery. 
Via Benzinga
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Global Growth Hits the Brakes: A Mixed Economic Picture Emerges for 2025 and Beyond
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade... 
Via MarketMinute
Topics Economy Supply Chain World Trade
P/E Ratio Insights for Johnson & Johnson
 
Via Benzinga
The Federal Reserve Under Siege: A Threat to Monetary Policy Independence
Concerns are escalating over the Federal Reserve's long-standing independence as political pressure intensifies, raising fundamental questions about the future of U.S. monetary policy and its... 
Via MarketMinute
Topics Bonds Economy Government
Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder. 
Via Benzinga
Navigating the Tempest: An Investor's Guide to the Volatile Bond Market of 2025
The global bond market is braced for continued turbulence in 2025, presenting a complex landscape for investors seeking stability and returns. A confluence of persistent inflation, central bank policy... 
Via MarketMinute
Topics Bonds Economy Retirement
Yield Curve Steeps Amidst Weakening Labor Market: A Looming Recession or Strategic Pivot for the US Economy?
The United States Treasury yield curve, a bellwether for economic sentiment, has undergone a dramatic transformation around April 2025, shifting from a historically prolonged inversion to a distinct... 
Via MarketMinute
Topics Bonds Economy Workforce
How Do Investors Really Feel About Johnson & Johnson?
 
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Investors Brace for Critical CPI Report as Inflation Nears 3% Hurdle
Financial markets are holding their breath as the highly anticipated August 2025 Consumer Price Index (CPI) report looms, a critical barometer for inflation and a potential swing factor for the Federal... 
Via MarketMinute
Topics Bonds Economy World Trade
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
From Johnson & Johnson
Via Business Wire
Will Sticky Services and Tariffs Spoil the Fed's Rate Cut Plans?
Despite widespread market expectations for a September interest rate cut, the Federal Reserve finds itself navigating a perilous economic landscape marked by persistently high inflation. Stubbornly... 
Via MarketMinute
Topics Economy World Trade
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
What does the future hold for Johnson & Johnson? In this episode, we break down the company's strengths, challenges, and what investors can expect moving forward. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
Global Equities Brace for a 'September Storm' as Tariffs and Political Turmoil Fuel Volatility
Global equity markets are bracing for a particularly tumultuous September, historically known as a challenging month for investors, now compounded by a fresh wave of geopolitical and domestic policy... 
Via MarketMinute
Topics Bonds Economy Fraud
Navigating the Choppy Waters: Economic Data, Geopolitics, Earnings, and Fed Policy Fuel Market Volatility
The financial markets are currently gripped by a palpable sense of unease, as a perfect storm of economic data, geopolitical events, corporate earnings, and Federal Reserve policy decisions conspire to... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?
The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Stagflationary Storm Brewing: OECD Warns of Dual Threat to US Economy in Late 2025
The U.S. economy is facing a concerning outlook for late 2025, with the Organisation for Economic Co-operation and Development (OECD) sounding the alarm on a potential "stagflation-lite" scenario. This... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Navigating the 'September Effect': Strategies for Investors in a Historically Volatile Month
As the summer fades and financial professionals return to their desks, the specter of the "September Effect"—a historical tendency for stock markets to deliver their weakest performance of the... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
There is more to like than the dividend with these companies. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Showcases Positive AFib Data, Treatment Results
Johnson & Johnson data shows VARIPULSE safety in AF procedures and Impella CP's long-term survival benefit in cardiogenic shock. 
Via Benzinga
Is Healthcare Setting Up to Be a Quiet Leader Into Year-End?
Over $11 billion flowed into the popular healthcare sector ETF XLV in Q2 alone, suggesting smart money is positioning for a potential rebound. 
Via MarketBeat
Topics ETFs
Market Jitters: Wall Street Braces for Continued Volatility
The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
These 4 Dividend Stocks Are Money-Printing Machines
These companies generate lots of cash to pass on to shareholders. 
Via The Motley Fool
The Great Rebalancing: Equity Markets Pivot from Tech Giants to Value and Cyclical Stocks
A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program
Johnson & Johnson ended a Phase 2a study of nipocalimab in rheumatoid arthritis after no added benefit was seen, but remains confident in its market potential. 
Via Benzinga
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.